{
    "clinical_study": {
        "@rank": "164975", 
        "arm_group": {
            "arm_group_label": "Gemtuzumab Ozogamicin", 
            "arm_group_type": "Experimental", 
            "description": "Consolidation therapy with GO will be administered between days 60 and 180 post transplantation when the ANC is >1000/mm3 and platelet count is >40,000/mm3 untransfused x 3 days after AlloSCT and again at minimum 8 weeks later."
        }, 
        "brief_summary": {
            "textblock": "Allogeneic stem cell transplantation followed by targeted immune therapy with Gemtuzumab\n      Ozogamicin (Mylotarg) will be given to patients with average risk AML or MDS."
        }, 
        "brief_title": "SCT Plus Immune Therapy in Average Risk AML/MDS", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Myelogenous Leukemia", 
            "Myelodysplastic Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Reduced intensity conditioning regimen of Busulfan and Fludarabine + Anti-Thymocyte Globulin\n      (unrelated donors only)] and AlloSCT followed by Gemtuzumab Ozogamicin consolidation in\n      patients with average risk AML/MDS meeting eligibility criteria."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Disease Status:\n\n          -  AML 1st CR with a matched family donor\n\n          -  AML 1st CR with unrelated donor\n\n          -  AML 2nd CR or CRP\n\n          -  MDS and < or = 5% bone marrow myeloblasts at diagnosis\n\n        Disease Immunophenotype:\n\n          -  Disease must express a minimum of > or = 10% CD33 positivity for patients with AML\n\n        Organ Function:\n\n          -  Adequate renal function, adequate liver function, adequate cardiac function, adequate\n             pulmonary function\n\n        Exclusion Criteria:\n\n          -  Patients with active CNS AML disease at time of preparative regimen\n\n          -  Secondary MDS\n\n          -  Poor cytogenetics\n\n          -  Female patients who are pregnant\n\n          -  Karnofsky <70% or Lansky <50% if 10 years or less\n\n          -  Age >30 years\n\n          -  Seropositive for HIV"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "30 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02117297", 
            "org_study_id": "NYMC-504", 
            "secondary_id": "L 10,394"
        }, 
        "intervention": {
            "arm_group_label": "Gemtuzumab Ozogamicin", 
            "description": "Gemtuzumab, 9.0 mg/m2, will be given IV over 2 hours two times post allogeneic transplantation.", 
            "intervention_name": "Gemtuzumab Ozogamicin", 
            "intervention_type": "Drug", 
            "other_name": "Mylotarg"
        }, 
        "intervention_browse": {
            "mesh_term": "Gemtuzumab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 15, 2014", 
        "location": {
            "contact": {
                "email": "mitchell_cairo@nymc.edu", 
                "last_name": "Mitchell S Cairo, MD", 
                "phone": "914-594-2150"
            }, 
            "contact_backup": {
                "email": "erin_morris@nymc.edu", 
                "last_name": "Erin Morris, RN", 
                "phone": "714-964-5359"
            }, 
            "facility": {
                "address": {
                    "city": "Vallhala", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10595"
                }, 
                "name": "New York Medical College"
            }, 
            "investigator": {
                "last_name": "Mitchell S. Cairo, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Allogeneic Stem Cell Transplantation Following by Targeted Immune Therapy) (Gemtuzumab Ozogamicin) in Average Risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome (AML/MDS)(IND 111024)", 
        "overall_contact": {
            "email": "mitchell_cairo@nymc.edu", 
            "last_name": "Mitchell S. Cairo, MD", 
            "phone": "(914) 594-2150"
        }, 
        "overall_contact_backup": {
            "email": "erin_morris@nymc.edu", 
            "last_name": "Erin Morris, RN", 
            "phone": "(714) 964-5359"
        }, 
        "overall_official": {
            "affiliation": "New York Medical College", 
            "last_name": "Mitchell S. Cairo, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "If three or more of the first ten patients experience primary or secondary graft failure, we will discontinue the study.", 
                "measure": "to evaluate incidence of graft failure", 
                "safety_issue": "No", 
                "time_frame": "Day +42"
            }, 
            {
                "description": "Event-free survival and overall survival after RI AlloSCT and targeted immunotherapy in patients with average risk AML/MDS.", 
                "measure": "to evaluate survival rates", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "to monitor for serious adverse events related to protocol investigational therapy", 
                "measure": "to determine toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02117297"
        }, 
        "responsible_party": {
            "investigator_affiliation": "New York Medical College", 
            "investigator_full_name": "Mitchell Cairo", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To measure the minor histocompatibility antigen expression on AML tissue, donor and recipient, and the development of MHA specific CTLs post AlloSCT.", 
                "measure": "Minor histocompatibility antigen", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "To determine the degree of mixed/complete donor chimerism after RI AlloSCT in patients with average risk AML/MDS.", 
                "measure": "Chimerism", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "To estimate the risk of acute and chronic GVHD following RI AlloSCT and FK506/MMF GVHD prophylaxis in patients with average risk AML/MDS.", 
                "measure": "Graft-versus-host disease", 
                "safety_issue": "No", 
                "time_frame": "1 Year"
            }
        ], 
        "source": "New York Medical College", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "New York Medical College", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}